Daniel A Shelly
CBDO PolTREG
Seminars
Wednesday 25th March 2026
Industry Leader’s Fireside Chat: Evaluating the Global Treg Landscape to Explore the Future of Space
8:40 am
- Exploring the global Treg landscape to identify emerging opportunities and the direction of future Treg development
- Exploring the interest in Treg collaboration and investment amid industry changes and recent changes in the industry
- Discussing the broad landscape of Treg therapy economics considering cost, reimbursement and tariff impacts
Wednesday 25th March 2026
CoRe-T: The CD6/CTLA4 CAR-Treg. A First-in-class T-cell Targeting and Treg Specific Signalling Treg Therapy
4:30 pm
- Introduction to CoRe-T (Counter Regulatory) CAR-Tregs: The CD6/CTLA-4 CAR-Treg
- Overview of Clinical Data in Chronic Refractory GvHD patients
- Shaping the future of targeted Treg therapies with multi-edited allogenic CAR-Tregs.
- Updates on PolTREG’s clinical pipeline and EMA’s agreement to receive submission of a Marketing Authorization for PTG-007 + Rituximab in Stage 3 T1D
